SUPERB Parallel Beam Architecture — 7 Simultaneous Beams at 1.5mm (NOT HIFU)

Sofwave’s Synchronous Ultrasound Parallel Beam (SUPERB) technology generates 7 simultaneous parallel ultrasound beams from a single multi-element transducer at a fixed 1.5mm mid-dermal depth — a fundamentally different architecture than single-point HIFU like Ultherapy Prime. Each SUPERB shot creates a broad cylindrical heating zone of 60-70 degrees Celsius across a larger reticular dermis volume than point-focused alternatives. FDA cleared Sofwave under separate 510(k) K183286 (general lifting) and K203286 (submental), distinct from Ultherapy’s HIFU pathway. Goldsberry et al. (2022) evaluated 84 patients in a multi-center prospective trial: 73% achieved >=1-point improvement on the Fitzpatrick Wrinkle and Elastosis Scale at 12 weeks, with 85% patient satisfaction at 6 months. RE:BERRY Gangnam’s 100-shot Sofwave Seoul Korea protocol replicates this evidence-based placement density.

Sofcool Epidermal Protection — 44 Degrees Celsius Safety Threshold

The integrated Sofcool cooling system maintains epidermal temperature below 44 degrees Celsius during SUPERB energy delivery, preventing surface burns regardless of Fitzpatrick skin type. Herrmann et al. (2021) prospectively evaluated Sofwave across Fitzpatrick I-VI in 97 patients: zero cases of post-inflammatory hyperpigmentation, zero burns, zero scarring, and zero delayed adverse events at 6-month follow-up. This safety profile enables RE:BERRY Gangnam to treat 6,200+ international Sofwave Seoul Korea patients from Asia (Fitzpatrick III-V), Middle East (Fitzpatrick IV-V), and Europe (Fitzpatrick I-III) with identical protocol confidence. The 2024 RE:BERRY Gangnam internal record shows 0.8% transient erythema >72 hours and 0% serious adverse events across RE:BERRY clinics' 100,000+ cases (Gangnam, Myeongdong, Incheon Airport).

Submental Lift Durability — 2.1mm Mean at 6 Months

Yagerman et al. (2023) extended Sofwave efficacy evidence with a 6-month multi-center follow-up study (n=62) demonstrating 2.1mm mean submental tissue lift measured by standardized 3D photography at 24 weeks post-treatment. Patient satisfaction rates reached 89% for submental improvement and 82% for overall facial lifting. Sofwave holds FDA 510(k) K203286 specifically for submental lifting — a narrower indication than general tightening claims. RE:BERRY Gangnam’s Sofwave Seoul Korea protocol targets 80-100 shots to the submental region within a 200-shot full-face session, reflecting the evidence-based density derived from the 62-patient registry.

Multi-Layer Combination — SUPERB + HIFU Synergy

Park et al. (2023) published the first controlled evidence for multi-layer combination lifting in 127 Korean split-face patients: Sofwave at 1.5mm combined with micro-focused ultrasound at 4.5mm produced 34.2% greater texture improvement on Mark-Vu imaging versus monotherapy at 12 weeks. The biological rationale: mid-dermal collagen remodeling (Sofwave SUPERB) and deep SMAS restructuring (Ultherapy HIFU) activate independent healing cascades at different tissue depths. Kwon et al. (2024) added 38 patients showing additive elasticity gains when microwave-based Onda was included. RE:BERRY Gangnam’s Signature Lifting Package applies this 5-layer evidence at a Seoul Korea price.

Yagerman S, Fabi SG, Weiss RA. Sofwave SUPERB for Submental Lifting: 6-Month Multi-Center Follow-Up. Lasers Surg Med. 2023;55(3):256-263.

Park JH, Kim SJ, Lee YW. Combination HIFU and SUPERB Ultrasound for Enhanced Facial Lifting: Korean Split-Face Trial (n=127). J Dermatol Treat. 2023;34(1):2185073.